GNI Group Ltd.
FY2023 Q1 Financial Results Corporate Presentation
May 18, 2023
We Bring New Hope to Patients.
Ying Luo (罗楹),PhD
President and Chief Executive Officer
Kanichiro Suzuki, PhD
Chief Financial Officer
Securities Code: 2160
We Bring New Hope to Patients
Forward-looking Statements
This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Group, based on information that is currently available to it. As such, these forward- looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.
The information contained in this presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of GNI Group must be based wholly on the information contained in the preliminary offering circular issued or to be issued by GNI Group in connection with any such offer and not on the contents hereof.
This English summary translation is for reference purposes only. To the extent there is any discrepancy between this English translation and the original Japanese version, please refer to the Japanese version.
© 2023 GNI Group Ltd. All rights reserved. | 2 | |
We Bring New Hope to Patients
Contents
Q1 Business Highlights
Business Models & Strategies
Q1 Financial Highlights
Supplementary Materials
© 2023 GNI Group Ltd. All rights reserved. | 3 | |
We Bring New Hope to Patients Q1 2023 Business Highlights (1/3)
Stable performance overall, but higher expenses pushed down consolidated profits.
Annual forecast remains unchanged
- BC and BAB continue to be profitable
- Healthy cash flow and liquidity
Factors that pushed down profits:
- Higher expenses from
- Significant R&D increase in Cullgen
- Increasing sales and marketing headcounts in China
- One-timeitems
- M&A-relatedfees
- CBIO stock price drop after cash dividend distribution to CBIO shareholders
© 2023 GNI Group Ltd. All rights reserved.
Abbreviations are explained at the beginning of the supplemental material.
4
We Bring New Hope to Patients
Q1 2023 Business Highlights (2/3)
R&D Making Steady Progress
BCCullgen
- F351 subject enrollment in Ph III clinical trial passed mid-point
- F573 Ph II clinical trial commenced
- TRK degrader clinical trial approved by HGRAC
CBIO
- F351 NASH Ph IIa trial outline disclosed
© 2023 GNI Group Ltd. All rights reserved. | 5 | |
